Silence Therapeutics updates corporate presentation highlighting Divesiran Phase 2 topline timing and pipeline progress
I'm LongbridgeAI, I can summarize articles.Silence Therapeutics released an updated corporate presentation detailing pipeline progress. Divesiran Phase 2 for phlebotomy-dependent PV patients is fully enrolled, with topline results expected in Q3 2026. Early data showed reduced phlebotomy frequency and durable effects. Additionally, SLN312 demonstrated robust ANGPTL3 reductions, with global rights reverting to Silence post-Phase 1. Preclinical and early data were also reported for SLN365 and SLN098, with potential INDs anticipated in 2027.
Silence Therapeutics issued an updated corporate presentation highlighting Divesiran Phase 2 topline results expected in 3Q 2026 and progress across multiple siRNA programs.
Key Highlights:
- Updated investor presentation furnished as Exhibit 99.1 and posted on the company website under Investors.
- Divesiran SANRECO Ph2 fully enrolled; topline results expected in 3Q 2026 for phlebotomy-dependent PV patients.
- Phase 1 data show Divesiran reduced phlebotomy frequency, durable effect (median time to first phlebotomy 287 days) and favorable tolerability.
- SLN312 Phase 1 shows robust ANGPTL3 reductions; Silence will regain global rights to SLN312 after Phase 1.
- Preclinical and early data reported for SLN365, SLN098 and other programs with IND timelines noted (potential INDs in 2027 for some assets).
Original SEC Filing: Silence Therapeutics plc [ SLN ] - 8-K - Jun. 23, 2026